Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed (22/05/2024)

26.05.2024

Marinomed: Marinomed Biotech AG (VSE:MARI) announces revenues of EUR 0.7 million recorded in the first quarter of 2024. After observing record revenues from Carragelose product sales heavily influenced by the SARS-CoV-2 pandemic over the past years, the revenue in the first quarter of 2024 has declined to levels observed before the pandemic. This decline is mostly due to high inventories and the return of seasonality, causing a drop in customer demand. Due to cost-conscious cash management, cash and cash equivalents stood at EUR 1.9 million compared to EUR 2.6 million at the end of 2023. The operating result (EBIT) stood at EUR -1.9 million (Q1 2023: EUR -1.4 million) and the loss for the period amounted to EUR -2.1 million (Q1 2023: EUR -2.1 million). “Although we are making constant progress and are working on several initiatives in parallel, the situation remains challenging. Revenues generated by the sales of Carragelose products will likely be characterized by the post-pandemic overhang of customers’ inventories and lower demand until the end of the year. Reaching an agreement with the EIB and real estate lenders to suspend repayments by 18 months has given us some more time and flexibility. At the same time, we have taken several measures to reduce the cash burn as much as possible”, Pascal Schmidt, CFO of Marinomed, adds. “However, closing deals with corresponding upfront and milestone payments for our Marinosolv assets remains our priority. At the same time, we are aiming for a decision regarding the evaluation of the whole Carragelose portfolio by the end of the first half of the year. We are optimistic that the cash flows generated from our efforts will be sufficient to cover our financing needs.”
Marinomed Biotech: weekly performance: -11.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/05/2024)


Partners









latest 21st Austria

21st Austria weekly - Marinomed (22/05/2024)


26.05.2024, 1872 Zeichen



Marinomed: Marinomed Biotech AG (VSE:MARI) announces revenues of EUR 0.7 million recorded in the first quarter of 2024. After observing record revenues from Carragelose product sales heavily influenced by the SARS-CoV-2 pandemic over the past years, the revenue in the first quarter of 2024 has declined to levels observed before the pandemic. This decline is mostly due to high inventories and the return of seasonality, causing a drop in customer demand. Due to cost-conscious cash management, cash and cash equivalents stood at EUR 1.9 million compared to EUR 2.6 million at the end of 2023. The operating result (EBIT) stood at EUR -1.9 million (Q1 2023: EUR -1.4 million) and the loss for the period amounted to EUR -2.1 million (Q1 2023: EUR -2.1 million). “Although we are making constant progress and are working on several initiatives in parallel, the situation remains challenging. Revenues generated by the sales of Carragelose products will likely be characterized by the post-pandemic overhang of customers’ inventories and lower demand until the end of the year. Reaching an agreement with the EIB and real estate lenders to suspend repayments by 18 months has given us some more time and flexibility. At the same time, we have taken several measures to reduce the cash burn as much as possible”, Pascal Schmidt, CFO of Marinomed, adds. “However, closing deals with corresponding upfront and milestone payments for our Marinosolv assets remains our priority. At the same time, we are aiming for a decision regarding the evaluation of the whole Carragelose portfolio by the end of the first half of the year. We are optimistic that the cash flows generated from our efforts will be sufficient to cover our financing needs.”
Marinomed Biotech: weekly performance: -11.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/05/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Zertifikate Party Österreich 06/24: Österreich braucht eine breite Kapitalmarkt-Bewegung, Ideen dazu beim ZFA Award Austria 2024




 

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, Immofinanz, Addiko Bank, Austriacard Holdings AG, Amag, RHI Magnesita, DO&CO, ATX, ATX Prime, ATX TR, Erste Group, Uniqa, RBI, UBM, Rosgix, EVN, voestalpine, Porr, Andritz, Frauenthal, Rosenbauer, Oberbank AG Stamm, Wolford, FACC, Agrana, CA Immo, Flughafen Wien, Österreichische Post, Telekom Austria, VIG, Wienerberger.


Random Partner

AVENTA AG
Die AVENTA AG ist ein Immobilienunternehmen mit Sitz in Graz, das von den Hauptaktionären Christoph Lerner und Bernhard Schuller geführt wird. Geschäftsschwerpunkt ist die Entwicklung von Wohnimmobilien von der Projektentwicklung über die technische Projektierung bis hin zu den fertigen Objekten.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten